<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sannaa W</submitter><funding>NIDDK NIH HHS</funding><funding>National Institutes of Health</funding><pagination>377-386</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9812862</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(2)</volume><pubmed_abstract>&lt;h4>Aim&lt;/h4>To identify patient factors, including gastrointestinal functions, that are predictive or associated with weight loss in response to once-daily 3 mg liraglutide administered subcutaneously (SQ) or placebo in obesity.&lt;h4>Methods&lt;/h4>One hundred and thirty-six obese adults (87% female) were randomized in a placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg administered SQ daily. Gastrointestinal functions were measured at baseline and 16 weeks: gastric emptying of solids (GET&lt;sub>1/2&lt;/sub> ); fasting and postprandial gastric volumes; kcal ingested during ad libitum buffet meal and the nutrient drink test. GET&lt;sub>1/2&lt;/sub> was also measured at 5 weeks. A multiple variable regression model examined variables associated with weight loss of more than 4 kg at 16 week</pubmed_abstract><journal>Diabetes, obesity &amp; metabolism</journal><pubmed_title>Factors associated with successful weight loss after liraglutide treatment for obesity.</pubmed_title><pmcid>PMC9812862</pmcid><funding_grant_id>R01‐DK67071</funding_grant_id><funding_grant_id>R01 DK067071</funding_grant_id><pubmed_authors>Dilmaghani S</pubmed_authors><pubmed_authors>Camilleri M</pubmed_authors><pubmed_authors>Maselli D</pubmed_authors><pubmed_authors>Harmsen WS</pubmed_authors><pubmed_authors>BouSaba J</pubmed_authors><pubmed_authors>Sannaa W</pubmed_authors><pubmed_authors>Eckert D</pubmed_authors><pubmed_authors>Taylor AL</pubmed_authors><pubmed_authors>Atieh J</pubmed_authors><pubmed_authors>Acosta A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Factors associated with successful weight loss after liraglutide treatment for obesity.</name><description>&lt;h4>Aim&lt;/h4>To identify patient factors, including gastrointestinal functions, that are predictive or associated with weight loss in response to once-daily 3 mg liraglutide administered subcutaneously (SQ) or placebo in obesity.&lt;h4>Methods&lt;/h4>One hundred and thirty-six obese adults (87% female) were randomized in a placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg administered SQ daily. Gastrointestinal functions were measured at baseline and 16 weeks: gastric emptying of solids (GET&lt;sub>1/2&lt;/sub> ); fasting and postprandial gastric volumes; kcal ingested during ad libitum buffet meal and the nutrient drink test. GET&lt;sub>1/2&lt;/sub> was also measured at 5 weeks. A multiple variable regression model examined variables associated with weight loss of more than 4 kg at 16 week</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-26T11:53:46.86Z</modification><creation>2025-02-19T04:59:43.509Z</creation></dates><accession>S-EPMC9812862</accession><cross_references><pubmed>36193713</pubmed><doi>10.1111/dom.14880</doi></cross_references></HashMap>